Drug intelligence / Profile preview

BT01

Development stage: Preclinical
Lead developer: BioTroy Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BT01 is a preclinical-stage, first-in-class monoclonal antibody being developed by BioTroy Therapeutics for the treatment of solid tumors, including gastric cancer and colorectal cancer. It targets semenogelin 2 (SEMG2), acting as an antagonist to modulate novel immuno-oncology mechanisms. BioTroy Therapeutics identified the key receptors and functions of this target, and the therapeutic potency of BT01 has been validated in multiple preclinical models. The drug is designed to interfere with tumor immune evasion by binding to receptors involved in tumor-immune interactions.

Beyond the preview

Go deeper on BT01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT01.

Explore the full profile